Blockchain Registration Transaction Record

Helus Pharma Corrects Release on TARA Mind Partnership for MDD Trial

Helus Pharma corrects press release on TARA Mind partnership for Phase 3 MDD trial, reaffirming alignment with executive order on mental health. HLP003 targets major depressive disorder.

This news matters because it highlights Helus Pharma's strategic correction to ensure accuracy in its communications about a partnership that could accelerate the development of a breakthrough treatment for major depressive disorder. For patients and veterans suffering from depression, the HLP003 program offers hope for a novel therapy that promotes neuroplasticity. The alignment with a recent executive order also signals government support for innovative mental health treatments, potentially expediting regulatory processes and broadening access to care. Investors should note the company's commitment to transparency and its progression into Phase 3 trials, which are critical steps toward market approval.